HealthDay News — A new blood test might improve doctors’ ability to track the spread of advanced melanoma, according to results of a small, preliminary study published in the January issue of Molecular Oncology.
The new test assesses levels of circulating tumor DNA (ctDNA) released into the blood when tumor cells die, the researchers said. Droplet digital polymerase chain reaction assays detecting BRAF and NRAS mutations were utilized in the study, which included 31 patients with unresectable stage IIIC/IV melanoma.
The researchers found that blood levels of ctDNA were elevated in 80% of patients about to undergo treatment for the advanced melanoma. Blood levels of lactate dehydrogenase (LDH) were elevated in just 30% of such patients. The ctDNA blood test detected cancer recurrence – confirmed by imaging – in 85% of patients tested and undergoing treatment. The LDH blood test detected 54% of such cases.
“Our study results show that circulating tumor DNA is a superior blood test for evaluating and tracking progression of metastatic melanoma,” senior investigator David Polsky, MD, PhD, from the NYU Langone Medical Center in New York City, said in a center news release.
- Chang GA, Tadepalli JS, Shao Y, et al. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. Mol Oncol. 2016;10(1):157-165. doi: 10.1016/j.molonc.2015.09.005